Verdict History and Settlement Projections
The talcum powder litigation has produced some of the largest product liability verdicts in American history. The $1.56 billion Craft verdict (December 2025), the $2.12 billion Ingham verdict (reduced on appeal from $4.69 billion, 2018), and the $117 million Lanzo verdict (2018) demonstrate that juries are willing to award extraordinary amounts when confronted with evidence of J&J’s decades-long concealment. The $700 million consumer class action settlement (2023) and the $850 million Imerys Talc Trust (2025) provide additional compensation frameworks.
Individual case values in the talcum powder litigation depend on several factors. Cancer type is the most significant variable — mesothelioma cases are generally valued higher than ovarian cancer cases because mesothelioma is almost always fatal and the asbestos causation link is stronger. Within ovarian cancer claims, the stage at diagnosis, the duration of talc use, the strength of medical records, and the availability of pathological evidence (talc particles in tumor tissue) all affect valuation.
Three compensation tiers have emerged. Tier I (moderate) encompasses cases with documented talc use and a cancer diagnosis but limited additional evidence, with projected settlements of $50,000 to $200,000. Tier II (significant) covers cases with long-term documented use and comprehensive medical records, with projected settlements of $200,000 to $1 million. Tier III (severe) addresses mesothelioma, advanced/fatal ovarian cancer, and wrongful death cases, with projected settlements of $1 million to $5 million or more.
The Imerys Talc Trust and Multiple Compensation Pathways
The Imerys Talc Trust, established when Imerys Talc America emerged from bankruptcy in August 2025, provides an additional avenue for compensation. The $850 million trust — funded by $505 million from J&J and the remainder from Imerys — is available to both current and future talc claimants. Trust claims may be filed in addition to direct claims against J&J through the MDL or state court proceedings.
The existence of multiple compensation pathways is important for plaintiffs. Claims against J&J through the MDL and state courts, claims through the Imerys Trust, and potential additional settlements as bellwether trial results accumulate all represent distinct avenues for recovery. An experienced talcum powder attorney can evaluate which combination of claims is most advantageous for your specific situation.
The contingency fee structure means families pay nothing upfront. Attorney fees are typically 33–40% of the total recovery, and all case costs are advanced by the law firm. The initial consultation is free and confidential. Filing early ensures your claim is preserved and positioned for the best possible outcome as the litigation moves toward resolution.
Scientific Evidence
IARC Monograph Volume 136: Talc and Acrylonitrile
International Agency for Research on Cancer Working Group. (2024). IARC Monographs on the Identification of Carcinogenic Hazards to Humans
Key Findings
- Limited but consistent evidence in humans from epidemiological studies showing increased ovarian cancer risk with perineal talc use across multiple study designs and populations
- Sufficient evidence of carcinogenicity in experimental animals, with talc causing tumors in multiple species and organ sites
- Strong mechanistic evidence including chronic inflammation, oxidative stress, altered cell proliferation, and epigenetic alterations in exposed tissues
- The upgrade to Group 2A reflects the accumulation of evidence since the 2006 Group 2B classification, including new large-scale epidemiological studies and improved mechanistic understanding
Prospective Cohort Studies of Talc Use and Ovarian Cancer Risk
Harvard Nurses’ Health Study / Women’s Health Initiative Investigators. (2020). Journal of the National Cancer Institute / Journal of Clinical Oncology
Key Findings
- Consistent positive association between perineal talc use and ovarian cancer risk, with hazard ratios typically ranging from 1.20 to 1.40
- Risk increased with duration of use, supporting a cumulative exposure model consistent with the chronic inflammation mechanism
- The association was strongest for serous ovarian cancer, the most common and lethal histological subtype
- Prospective study design provides stronger causal inference than case-control studies because talc use was reported before cancer diagnosis, eliminating recall bias
Perineal Talc Use and Ovarian Cancer Risk: A Case-Control Study
Cramer DW, Welch WR, Scully RE, Wojciechowski CA. (1982). The Lancet
Key Findings
- Women who used talcum powder for perineal hygiene had an odds ratio of 1.92 for ovarian cancer compared to non-users
- The risk increased with frequency and duration of use, suggesting a dose-response relationship
- The study proposed the talc migration pathway: particles travel from the perineal area through the reproductive tract to the ovarian surface
- Results were consistent across multiple cancer histological subtypes, supporting a general carcinogenic mechanism rather than subtype-specific effect
Frequently Asked Questions
Related Pages
Talcum Powder & Asbestos Contamination
Asbestos contamination in J&J’s talcum powder products is a central pillar of the litigation. Talc and asbestos co-occur naturally in geological deposits, and J&J’s internal documents show the company knew its talc supply was contaminated since the 1970s. The FDA confirmed asbestos in Baby Powder in 2019. Asbestos is a Group 1 carcinogen with no safe level of exposure — its presence in a product marketed for daily intimate use represents a catastrophic product safety failure.
Baby Powder Cancer Lawsuit
Johnson & Johnson’s Baby Powder is the product at the center of the talcum powder litigation. Marketed for over a century as safe and gentle, Baby Powder has been linked to ovarian cancer and mesothelioma through both its talc content and asbestos contamination. J&J discontinued talc-based Baby Powder in North America in 2020 and globally in 2022, but the damage to millions of consumers who trusted the product spans decades.
Johnson & Johnson Talc Lawsuit
Johnson & Johnson is the primary defendant in the talcum powder litigation, facing more than 63,000 lawsuits alleging its Baby Powder and Shower to Shower products caused ovarian cancer and mesothelioma. Internal documents show J&J knew of asbestos contamination since the 1970s. The company’s "Texas two-step" bankruptcy strategy to cap liability was rejected by the Third Circuit. J&J faces continued trial exposure with the MDL 2738 bellwether proceedings.
Talcum Powder & Mesothelioma
Mesothelioma from asbestos-contaminated talcum powder represents a distinct and extremely serious category of claims in the talc litigation. Unlike the ovarian cancer claims, which involve the carcinogenic properties of talc itself, mesothelioma claims are based on asbestos contamination in J&J products — confirmed by J&J’s own internal documents and FDA testing. The $117 million Lanzo verdict in New Jersey established that juries will hold J&J liable for mesothelioma from contaminated Baby Powder.
Talcum Powder & Ovarian Cancer
Ovarian cancer is the cancer most strongly linked to talcum powder use. Four decades of epidemiological research — beginning with the 1982 Cramer et al. study in The Lancet — have consistently demonstrated that women who use talcum powder for perineal hygiene face elevated ovarian cancer risk. The IARC upgraded talc to Group 2A ("probably carcinogenic") in 2024. Women diagnosed with ovarian cancer after long-term Baby Powder use may qualify for significant compensation.
Talcum Powder Statute of Limitations
The statute of limitations for talcum powder lawsuits varies by state, typically ranging from 2 to 5 years. The "discovery rule" is critical in talc cases because cancers may develop decades after exposure — the clock typically starts when you were diagnosed or when you discovered the connection between your cancer and talcum powder use, not when you first used the product. Filing promptly is essential because deadlines are strict and irreversible.
Talcum Powder Wrongful Death Claims
Wrongful death claims are a significant component of the talcum powder litigation. Thousands of women have died from ovarian cancer linked to Baby Powder use, and mesothelioma from asbestos-contaminated talc is nearly always fatal. Surviving family members can file wrongful death claims to recover damages including medical expenses, funeral costs, lost financial support, and compensation for the loss of their loved one’s companionship and guidance.
Talcum Powder Lawsuit
Talcum powder litigation is one of the largest and most consequential mass tort actions in American history. More than 63,000 lawsuits have been filed against Johnson & Johnson and its talc supplier Imerys, alleging that decades of Baby Powder use caused ovarian cancer, mesothelioma, and other cancers. The litigation centers on two distinct but related harms: the carcinogenic properties of talc itself when applied to the perineal area, and asbestos contamination in talc products traced to mining operations. Juries across the country have returned billions of dollars in verdicts, including a $4.69 billion verdict in St. Louis (later reduced to $2.12 billion on appeal) and a $1.56 billion verdict in Baltimore in December 2025. J&J discontinued talc-based Baby Powder in North America in 2020 and globally in 2022, replacing it with cornstarch. The MDL 2738 in the District of New Jersey, now before Judge Michael Shipp, is coordinating federal proceedings with bellwether trials underway.
View full case overview